Table 4.
Avidity of serum IgA and IgG antibodies in A(H5N2) LAIV-primed and control subjects immunized with one dose of A(H5N1) IIV at indicated time points
| n (%) of subjects with ≥15% increase of AI2 |
Mean AI |
|||||||
|---|---|---|---|---|---|---|---|---|
| Test antigen | Ab | Group | n1 | Day 7 | Day 28 | Day 0 | Day 7 | Day 28 |
| 17/t/Tur (H5N2) | IgA | Primed | 14 | 6 (42.9) | 5 (35.7) | 75.6 ± 14.6 | 87.7 ± 9.3 | 87.2 ± 8.6 |
| Control | 9 | 2 (22.2) | 1 (11.1) | 75.2 ± 8.6 | 81.5 ± 10.3 | 85.1 ± 7.8 | ||
| IgG | Primed | 11 | 5 (45.5) | 6 (54.5) | 81.6 ± 11.8 | 90.7 ± 5.7 | 92.3 ± 6.4 | |
| Control | 11 | 1 (9.1) | 1 (9.1) | 83.4 ± 9.7 | 86.0 ± 12.0 | 84.2 ± 10.5 | ||
| NIBRG-23 (H5N1) | IgA | Primed | 17 | 9 (52.9) | 7 (41.2) | 72.7 ± 7.5 | 86.4 ± 12.6 | 84.9 ± 8.8 |
| Control | 16 | 3 (18.8) | 0 (0.0) | 77.4 ± 6.4 | 83.3 ± 8.1 | 77.9 ± 8.3 | ||
| IgG | Primed | 11 | 2 (18.2) | 6 (54.5) | 76.2 ± 4.9 | 86.2 ± 10.6 | 90.6 ± 14.2 | |
| Control | 17 | 0 (0.0) | 3 (17.6) | 78.3 ± 8.2 | 78.0 ± 9.1 | 77.9 ± 15.8 | ||
17/t/Tur (H5N2): A/17/turkey/Turkey/05/133 (H5N2) LAIV strain; NIBRG-23 (H5N1): A/turkey/Turkey/5/05 (H5N1) PR8-based candidate vaccine virus; Ab – antibody;
1
number of subjects with seroconversion.
2
AI – avidity index (OD450 with urea / OD450 without urea × 100%).
3
significantly higher rates in one group compared to another are shown in bold (p < 0.05).